GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » Sale Of Investment

Sunho Biologics (HKSE:02898) Sale Of Investment : HK$93.92 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics Sale Of Investment?

Sunho Biologics's sale of investment for the six months ended in Dec. 2024 was HK$0.12 Mil. It means Sunho Biologics gained HK$0.12 Mil from selling investments. Sunho Biologics's sale of investment for the trailing twelve months (TTM) ended in Dec. 2024 was HK$93.92 Mil.

Compared with last quarter (HK$93.79 Mil in Jun. 2024 ), Sunho Biologics gained less money from selling investments in Dec. 2024 (HK$0.12 Mil).


Sunho Biologics Sale Of Investment Historical Data

The historical data trend for Sunho Biologics's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics Sale Of Investment Chart

Sunho Biologics Annual Data
Trend Dec22 Dec23 Dec24
Sale Of Investment
19.61 - 93.15

Sunho Biologics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24
Sale Of Investment - - - 93.79 0.12

Sunho Biologics Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$93.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunho Biologics Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Sunho Biologics's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunho Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
Executives
Sunho Fortune Investments Limited 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Zhang Feng 2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited 2101 Beneficial owner

Sunho Biologics Headlines

No Headlines